Cara M Statz1, Sara E Patterson1, Susan M Mockus2. 1. The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT, USA. 2. The Jackson Laboratory for Genomic Medicine, 10 Discovery Drive, Farmington, CT, USA. susan.mockus@jax.org.
Abstract
BACKGROUND: The progression of prostate cancer to castration-resistant prostate cancer (CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, suggesting that therapies targeting this pathway might lead to improved survival and efficacy. Here, we systematically evaluate the results of clinical trials investigating mTOR inhibition in CRPC and utilize preclinical data to predict clinical outcomes. METHODS: Trials included in the study were identified through PubMed and via review of conference abstracts cited by relevant review articles. The eligibility of trials was independent of sample size, clinical setting, or date. RESULTS: A total of 14 studies were eligible for qualitative analysis. The clinical setting was variable among studies, and all utilized an allosteric mTOR inhibitor as either a monotherapy or in combination. Molecular criteria were evaluated in three trials. Among most studies, the prostate-specific antigen level declined during treatment, but often increased shortly thereafter. Partial responses to treatment were minimal, and no complete responses were reported. Two studies exploring therapy with an mTOR inhibitor in combination with bicalutamide resulted in minimal efficacy. Overall, allosteric mTOR inhibition was deemed to be inadequate for the treatment of CRPC. CONCLUSION: Preclinical data suggest that a reciprocal feedback mechanism between PI3K and androgen receptor signaling is a potential mechanism behind the clinical inefficacy of mTOR inhibitors in CRPC, indicating combinatorial targeting of PI3K, mTORC1/2, and the androgen receptor might be more effective. Comprehensive analysis of preclinical data to assess clinical trial targets and efficacy may reduce the number of unproductive trials and identify potentially beneficial combinatorial therapies for resistant disease.
BACKGROUND: The progression of prostate cancer to castration-resistant prostate cancer (CRPC) is often a result of somatic alterations in the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, suggesting that therapies targeting this pathway might lead to improved survival and efficacy. Here, we systematically evaluate the results of clinical trials investigating mTOR inhibition in CRPC and utilize preclinical data to predict clinical outcomes. METHODS: Trials included in the study were identified through PubMed and via review of conference abstracts cited by relevant review articles. The eligibility of trials was independent of sample size, clinical setting, or date. RESULTS: A total of 14 studies were eligible for qualitative analysis. The clinical setting was variable among studies, and all utilized an allosteric mTOR inhibitor as either a monotherapy or in combination. Molecular criteria were evaluated in three trials. Among most studies, the prostate-specific antigen level declined during treatment, but often increased shortly thereafter. Partial responses to treatment were minimal, and no complete responses were reported. Two studies exploring therapy with an mTOR inhibitor in combination with bicalutamide resulted in minimal efficacy. Overall, allosteric mTOR inhibition was deemed to be inadequate for the treatment of CRPC. CONCLUSION: Preclinical data suggest that a reciprocal feedback mechanism between PI3K and androgen receptor signaling is a potential mechanism behind the clinical inefficacy of mTOR inhibitors in CRPC, indicating combinatorial targeting of PI3K, mTORC1/2, and the androgen receptor might be more effective. Comprehensive analysis of preclinical data to assess clinical trial targets and efficacy may reduce the number of unproductive trials and identify potentially beneficial combinatorial therapies for resistant disease.
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Aimee L Edinger; Corinne M Linardic; Gary G Chiang; Craig B Thompson; Robert T Abraham Journal: Cancer Res Date: 2003-12-01 Impact factor: 12.701
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Mari Nakabayashi; Lilian Werner; Kevin D Courtney; Geoffrey Buckle; William K Oh; Glen J Bubley; Julia H Hayes; Douglas Weckstein; Aymen Elfiky; Danny M Sims; Philip W Kantoff; Mary-Ellen Taplin Journal: BJU Int Date: 2012-08-29 Impact factor: 5.588
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu Journal: Cancer Cell Date: 2003-09 Impact factor: 31.743
Authors: Emanuela Dylgjeri; Christopher McNair; Jonathan F Goodwin; Heather K Raymon; Peter A McCue; Ayesha A Shafi; Benjamin E Leiby; Renée de Leeuw; Vishal Kothari; Jennifer J McCann; Amy C Mandigo; Saswati N Chand; Matthew J Schiewer; Lucas J Brand; Irina Vasilevskaya; Nicolas Gordon; Talya S Laufer; Leonard G Gomella; Costas D Lallas; Edouard J Trabulsi; Felix Y Feng; Ellen H Filvaroff; Kristin Hege; Dana Rathkopf; Karen E Knudsen Journal: Clin Cancer Res Date: 2019-07-02 Impact factor: 12.531
Authors: Dominik Awad; Thomas L Pulliam; Chenchu Lin; Sandi R Wilkenfeld; Daniel E Frigo Journal: Curr Opin Pharmacol Date: 2018-03-30 Impact factor: 5.547
Authors: Se Un Jeong; Anuja Kashikar Kekatpure; Ja-Min Park; Minkyu Han; Hee Sang Hwang; Hui Jeong Jeong; Heounjeong Go; Yong Mee Cho Journal: J Pathol Transl Med Date: 2017-08-09
Authors: Étienne Audet-Walsh; Catherine R Dufour; Tracey Yee; Fatima Z Zouanat; Ming Yan; Georges Kalloghlian; Mathieu Vernier; Maxime Caron; Guillaume Bourque; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Armen G Aprikian; Jacques Lapointe; Simone Chevalier; Vincent Giguère Journal: Genes Dev Date: 2017-07-19 Impact factor: 11.361